COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

Protocol No
Principal Investigator
Mehdi Hamadani
Your type of cancer may have higher than normal levels of certain enzymes (proteins) called cytidine deaminases that can result in breaks in cellular DNA and help foster tumor growth. These enzymes depend on RAD-51, a protein that helps with repairing the breaks in DNA (DNA repair). If RAD-51 is inhibited, cancer cells may die. CYT-0851 is being studied as a possible way to help stop or slow the spread of cancer cells and may help shrink tumors. We are doing this study to see what dose of CYT-0851 is safe for patients and is the most effective dose for stopping the growth of your cancer.
his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.
Participating Institutions
Froedtert Hospital